Alan J Thompson1. 1. Institute of Neurology, University College London and National Hospital for Neurology and Neurosurgery, University College London Hospital, London, UK. a.thompson@ion.ucl.ac.uk
Abstract
PURPOSE OF REVIEW: This review of recent work in the area of neurorehabilitation of multiple sclerosis patients surveys progress and underscores the need for further work to evaluate the effectiveness of treatments. RECENT FINDINGS: Several recent review documents have summarized the current position regarding neurorehabilitation and symptomatic management in multiple sclerosis. They have highlighted the paucity of evidence underpinning current practice, thereby identifying the need for more scientifically sound studies in both neurorehabilitation and symptomatic treatment. However, as will be apparent from this review, there has been a welcome increase in studies evaluating both aspects of neurorehabilitation and specific areas such as the role of cannabinoids in spasticity and pain and new treatments for cognitive impairment. SUMMARY: Overall, there is an encouraging trend both in questioning our current practice and in designing more scientifically sound trials incorporating new and more appropriate outcome measures. There is, however, much more to be done before we are in a position to provide the expert, comprehensive, joined-up, care that is required to meet the complex, ever-changing needs of patients with multiple sclerosis.
PURPOSE OF REVIEW: This review of recent work in the area of neurorehabilitation of multiple sclerosispatients surveys progress and underscores the need for further work to evaluate the effectiveness of treatments. RECENT FINDINGS: Several recent review documents have summarized the current position regarding neurorehabilitation and symptomatic management in multiple sclerosis. They have highlighted the paucity of evidence underpinning current practice, thereby identifying the need for more scientifically sound studies in both neurorehabilitation and symptomatic treatment. However, as will be apparent from this review, there has been a welcome increase in studies evaluating both aspects of neurorehabilitation and specific areas such as the role of cannabinoids in spasticity and pain and new treatments for cognitive impairment. SUMMARY: Overall, there is an encouraging trend both in questioning our current practice and in designing more scientifically sound trials incorporating new and more appropriate outcome measures. There is, however, much more to be done before we are in a position to provide the expert, comprehensive, joined-up, care that is required to meet the complex, ever-changing needs of patients with multiple sclerosis.
Authors: Valentina Tomassini; Heidi Johansen-Berg; Laura Leonardi; Luis Paixão; Saad Jbabdi; Jackie Palace; Carlo Pozzilli; Paul M Matthews Journal: Mult Scler Date: 2010-09-10 Impact factor: 6.312
Authors: Valentina Tomassini; Paul M Matthews; Alan J Thompson; Daniel Fuglø; Jeroen J Geurts; Heidi Johansen-Berg; Derek K Jones; Maria A Rocca; Richard G Wise; Frederik Barkhof; Jacqueline Palace Journal: Nat Rev Neurol Date: 2012-11-05 Impact factor: 42.937
Authors: Ilona Lipp; Catherine Foster; Rachael Stickland; Eleonora Sgarlata; Emma C Tallantyre; Alison E Davidson; Neil P Robertson; Derek K Jones; Richard G Wise; Valentina Tomassini Journal: Mult Scler Date: 2020-08-04 Impact factor: 6.312